MCID: ATM017
MIFTS: 49

Autoimmune Disease of the Nervous System

Categories: Immune diseases, Neuronal diseases

Aliases & Classifications for Autoimmune Disease of the Nervous System

MalaCards integrated aliases for Autoimmune Disease of the Nervous System:

Name: Autoimmune Disease of the Nervous System 12 15
Autoimmune Diseases of the Nervous System 44
Autoimmune Nervous System Disorder 12
Autoimmune Diseases Nervous System 55

Classifications:



External Ids:

Disease Ontology 12 DOID:438
MeSH 44 D020274
NCIt 50 C99383
UMLS 73 C0751871

Summaries for Autoimmune Disease of the Nervous System

MalaCards based summary : Autoimmune Disease of the Nervous System, also known as autoimmune diseases of the nervous system, is related to autoimmune disease of peripheral nervous system and alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity. An important gene associated with Autoimmune Disease of the Nervous System is MBP (Myelin Basic Protein), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Prednisolone phosphate and Prednisolone have been mentioned in the context of this disorder. Affiliated tissues include lung, skin and brain, and related phenotypes are hematopoietic system and homeostasis/metabolism

Related Diseases for Autoimmune Disease of the Nervous System

Diseases in the Nervous System Disease family:

Autoimmune Disease of Central Nervous System Congenital Nervous System Abnormality
Central Nervous System Disease Autoimmune Disease of the Nervous System

Diseases related to Autoimmune Disease of the Nervous System via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 353)
# Related Disease Score Top Affiliating Genes
1 autoimmune disease of peripheral nervous system 31.8 DDX41 MAG MBP MOG TNF
2 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 30.8 FOXP3 IFNG IL10 IL17A
3 autoimmune disease 30.0 FOXP3 HLA-DRB1 IFNG IL10 IL17A IL1B
4 multiple sclerosis 29.2 AQP4 FOXP3 HLA-DRB1 IFNB1 IFNG IL10
5 allergic encephalomyelitis 10.4 MBP MOG
6 neonatal myasthenia gravis 10.4 AQP4 MUSK
7 palladium allergic contact dermatitis 10.4 IL10 IL17A
8 autoimmune atherosclerosis 10.4 FOXP3 IL10
9 cephalosporin allergy 10.4 IFNG IL10
10 multifocal choroiditis 10.4 IL10 TNF
11 angioimmunoblastic lymphadenopathy with dysproteinemia 10.4 IL6 TNF
12 punctate inner choroidopathy 10.4 IL10 TNF
13 retroperitoneal neuroblastoma 10.4 IFNB1 IL2
14 exudative glomerulonephritis 10.4 IL1B TNF
15 acute necrotizing encephalitis 10.4 FOXP3 IFNG
16 leukomalacia 10.4 IL6 TNF
17 scorpion envenomation 10.4 IL6 TNF
18 oral tuberculosis 10.4 IL2 TNF
19 recurrent corneal erosion 10.4 IL1B IL6
20 neuroretinitis 10.4 AQP4 IFNB1 MOG
21 bagassosis 10.4 IL1B IL6
22 variola major 10.4 IFNG IL2
23 juvenile myasthenia gravis 10.4 HLA-DRB1 IL10
24 cranial nerve disease 10.4 AQP4 MBP MOG
25 paraneoplastic syndromes 10.4 IL1B IL6
26 mesial temporal lobe epilepsy with hippocampal sclerosis 10.4 HLA-DRB1 IL1B
27 fixed drug eruption 10.4 IFNG IL2
28 meningoencephalitis 10.4 IL6 MBP TLR9
29 keratitis, hereditary 10.4 IL17A IL1B TLR9
30 virus associated hemophagocytic syndrome 10.4 IL2 IL4
31 mucocutaneous leishmaniasis 10.4 IL10 TLR9 TNF
32 irritable bowel syndrome 10.4 IL10 TLR9 TNF
33 trichosporonosis 10.4 IFNG IL17A TNF
34 severe acute respiratory syndrome 10.4 IFNB1 IFNG TNF
35 viral pneumonia 10.4 IL17A IL6 TLR9
36 filarial elephantiasis 10.4 IL10 IL4 TLR9
37 dry eye syndrome 10.4 IL6 TLR9 TNF
38 nasal cavity disease 10.4 IL10 IL4 TLR9
39 periventricular leukomalacia 10.4 IL6 MBP TNF
40 myositis fibrosa 10.4 IFNG IL17A TLR9
41 spinal cord injury 10.4 AQP4 IL6 TNF
42 reproductive system disease 10.4 IL6 TLR9 TNF
43 hypersensitivity reaction type iii disease 10.4 IL6 TLR9 TNF
44 tungiasis 10.4 IL10 IL4 TNF
45 female reproductive system disease 10.4 IL6 TLR9 TNF
46 spotted fever 10.4 IFNG IL10 TNF
47 gastrointestinal system cancer 10.4 IL6 TLR9 TNF
48 genital herpes 10.4 IL10 IL4 TLR9
49 hepatitis a 10.4 IFNG IL10 TNF
50 ileitis 10.3 IL17A IL6 TNF

Graphical network of the top 20 diseases related to Autoimmune Disease of the Nervous System:



Diseases related to Autoimmune Disease of the Nervous System

Symptoms & Phenotypes for Autoimmune Disease of the Nervous System

MGI Mouse Phenotypes related to Autoimmune Disease of the Nervous System:

46 (show all 19)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.43 AQP4 FOXP3 IFNB1 IFNG IL10 IL17A
2 homeostasis/metabolism MP:0005376 10.41 AQP4 FOXP3 IFNB1 IFNG IL10 IL17A
3 immune system MP:0005387 10.4 AQP4 FOXP3 IFNB1 IFNG IL10 IL17A
4 cellular MP:0005384 10.35 FOXP3 IFNG IL10 IL2 IL4 IL6
5 growth/size/body region MP:0005378 10.35 AQP4 FOXP3 IFNG IL10 IL17A IL1B
6 behavior/neurological MP:0005386 10.32 AQP4 FOXP3 IFNG IL10 IL2 IL6
7 mortality/aging MP:0010768 10.31 AQP4 DDX41 FOXP3 IFNG IL10 IL17A
8 digestive/alimentary MP:0005381 10.26 AQP4 FOXP3 IFNG IL10 IL17A IL2
9 nervous system MP:0003631 10.21 AQP4 IFNB1 IFNG IL10 IL1B IL4
10 endocrine/exocrine gland MP:0005379 10.2 AQP4 FOXP3 IFNG IL10 IL17A IL2
11 craniofacial MP:0005382 10.11 FOXP3 IFNG IL10 IL17A IL1B IL4
12 integument MP:0010771 10.08 FOXP3 IFNG IL10 IL1B IL4 IL6
13 no phenotypic analysis MP:0003012 10.02 AQP4 FOXP3 IFNB1 IFNG IL10 IL17A
14 liver/biliary system MP:0005370 10 FOXP3 IFNG IL10 IL2 IL4 IL6
15 neoplasm MP:0002006 9.95 IFNB1 IFNG IL10 IL1B IL2 IL6
16 respiratory system MP:0005388 9.85 AQP4 FOXP3 IFNG IL10 IL17A IL2
17 renal/urinary system MP:0005367 9.8 AQP4 FOXP3 IFNG IL17A IL4 IL6
18 skeleton MP:0005390 9.61 IFNB1 IFNG IL10 IL17A IL1B IL4
19 vision/eye MP:0005391 9.4 AQP4 FOXP3 IFNG IL10 IL2 IL4

Drugs & Therapeutics for Autoimmune Disease of the Nervous System

Drugs for Autoimmune Disease of the Nervous System (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 626)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 302-25-0
2
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
3
Natalizumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 189261-10-7
4
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
5
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2921-57-5
6
4-Aminopyridine Approved Phase 4,Phase 3,Phase 2,Not Applicable 504-24-5 1727
7
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53-03-2 5865
8
Mycophenolic acid Approved Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1 24280-93-1 446541
9
Interferon beta-1b Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 145155-23-3
10
Mitoxantrone Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 65271-80-9 4212
11
rituximab Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 174722-31-7 10201696
12
Interferon beta-1a Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 145258-61-3 6438354
13
alemtuzumab Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 216503-57-0
14
Titanium dioxide Approved Phase 4,Phase 2 13463-67-7
15
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 94-09-7, 1994-09-7 2337
16 tannic acid Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
17
Dopamine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 51-61-6, 62-31-7 681
18
Memantine Approved, Investigational Phase 4,Phase 2,Phase 3 19982-08-2 4054
19
Simvastatin Approved Phase 4,Phase 3,Phase 2 79902-63-9 54454
20
Mannitol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 69-65-8 453 6251
21
Methotrexate Approved Phase 4,Phase 3,Phase 2,Early Phase 1 59-05-2, 1959-05-2 126941
22
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-05-9 6006 143
23
Azathioprine Approved Phase 4,Phase 2,Phase 3,Not Applicable 446-86-6 2265
24
Armodafinil Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 112111-43-0
25
Modafinil Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 68693-11-8 4236
26
Lamotrigine Approved, Investigational Phase 4,Phase 2 84057-84-1 3878
27
Topiramate Approved Phase 4,Phase 2 97240-79-4 5284627
28
Pseudoephedrine Approved Phase 4,Phase 1,Phase 2 90-82-4 7028
29
Ephedrine Approved Phase 4,Phase 1,Phase 2 299-42-3 9294
30
Phytonadione Approved, Investigational Phase 4,Phase 3 84-80-0 4812 5284607
31
Dimethyl fumarate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 624-49-7 637568 5271565
32
Montelukast Approved Phase 4,Phase 1,Phase 2 158966-92-8 5281040
33
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7 4594 9579578
34
Acetaminophen Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 103-90-2 1983
35
Ranitidine Approved Phase 4,Phase 3 66357-35-5, 66357-59-3 3001055
36
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 51-45-6, 75614-87-8 774
37
Acyclovir Approved Phase 4,Phase 3,Phase 1 59277-89-3 2022
38
Ibuprofen Approved Phase 4,Phase 3 15687-27-1 3672
39
Cetirizine Approved Phase 4,Phase 1,Phase 2 83881-51-0 2678
40
Aspirin Approved, Vet_approved Phase 4,Phase 3,Early Phase 1 50-78-2 2244
41
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-84-3 187
42
Peppermint Approved Phase 4,Phase 3
43
Ethanol Approved Phase 4,Phase 3 64-17-5 702
44
Peppermint oil Approved, Investigational Phase 4,Phase 3 8006-90-4
45
Dronabinol Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1 1972-08-3 16078
46
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 57-27-2 5288826
47
Tocopherol Approved, Investigational Phase 4,Phase 1,Phase 2 1406-66-2 14986
48
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
49
Lubiprostone Approved, Investigational Phase 4 136790-76-6 656719
50
Iron Approved Phase 4,Early Phase 1 7439-89-6 23925

Interventional clinical trials:

(show top 50) (show all 2079)
# Name Status NCT ID Phase Drugs
1 Antispastic Effect of Transcranial Magnetic Stimulation in Patients With Cerebral and Spinal Spasticity Unknown status NCT01786005 Phase 4
2 Methylprednisolone During the Switch Between Natalizumab and Fingolimod Unknown status NCT02769689 Phase 4 Methylprednisolone;Placebo;natalizumab (NTZ);fingolimob (FTY)
3 Study to Assess Immune Function and MRI Disease Activity in RRMS Patients When Switching From Natalizumab to Gilenya Unknown status NCT02325440 Phase 4 Fingolimod;Natalizumab
4 Efficacy of Dalfampridine on Upper Extremity Function in Patients With MS Unknown status NCT02259361 Phase 4 Sustained-release oral dalfampridine;Placebo
5 Mycophenolate Mofetil Treatment With Neuromyelitis Optica Spectrum Disorders in Chinese Patients Unknown status NCT02809079 Phase 4 Mycophenolate mofetil;Prednisone
6 Impact of Vitamin A on RAR Gene Expression in Multiple Sclerosis Unknown status NCT01705457 Phase 4 Dietary Supplement: vitamin A;placebo
7 Impact of Vitamin A on Multiple Sclerosis (MS) Unknown status NCT01417273 Phase 4 Drug: placebo
8 Impact of Vitamin A on Gene Expression, in Multiple Sclerosis Patient Unknown status NCT01407211 Phase 4
9 Colecalciferol as an Add-on Treatment to Interferon-beta-1b for Treatment of Multiple Sclerosis (MS) Unknown status NCT01339676 Phase 4 Colecalciferol;Placebo capsules
10 Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders Unknown status NCT02021825 Phase 4 Mitoxantrone
11 Optical Coherence Tomography: Glatiramer in Clinically Isolated Syndrome or Early Relapsing Remitting Multiple Sclerosis (MS) Unknown status NCT00910598 Phase 4 glatiramer acetate
12 IVIg for Demyelination in Diabetes Mellitus Unknown status NCT02372149 Phase 4 10% intravenous immunoglobulin (IVIg);0.9% sodium chloride
13 Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI Unknown status NCT00176592 Phase 4 Betaseron;Copaxone
14 Steroids Pharmacokinetics and the Response to Prednisone Therapy in Giant Cell Arteritis Unknown status NCT01400464 Phase 4 Prednisone therapy and pharmacokinetic
15 A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease) Completed NCT00304291 Phase 4 Mitoxantrone
16 Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases Completed NCT02040116 Phase 4 Rituximab Infusion
17 Effects of Vitamin K on Redness Associated With Injection Site Reactions in Participants Treated With Plegridy Completed NCT03091569 Phase 4
18 Natalizumab Temporary Discontinuation Study Completed NCT02775110 Phase 4
19 Tecfidera and the Gut Microbiota Completed NCT02471560 Phase 4 dimethyl fumarate;injectable MS DMT
20 Prolonged-release Fampridine as Adjunct Therapy to Active Motor Training in MS Patients Completed NCT02146534 Phase 4 extended release fampridine;Placebo
21 MATRIX: Measuring Neutralizing Antibodies in the Patients Treated With Interferon Beta 1a IM, in Mexico and Colombia Completed NCT01556685 Phase 4
22 A Study to Evaluate the Impact of Using Warm Compress Prior to Daily Injections of Copaxone® Completed NCT00239993 Phase 4 glatiramer acetate
23 BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies Completed NCT03269175 Phase 4
24 Follow up Study of Patients on Fingolimod Who Were Enrolled in the Original Biobank Study (CFTY720DDE01) Completed NCT02720107 Phase 4
25 Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers Completed NCT02683863 Phase 4 BG00012 (DMF) (Tecfidera®.)
26 Plegridy Satisfaction Study in Participants Completed NCT02587065 Phase 4 peginterferon beta-1a
27 Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone® Completed NCT02499900 Phase 4 Copaxone®
28 Investigation of the Effect of Dimethyl Fumarate on T Cells in Patients With Relapsing Remitting Multiple Sclerosis Completed NCT02461069 Phase 4 Dimethyl fumarate
29 Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera Completed NCT02410278 Phase 4 dimethyl fumarate;montelukast;Placebo
30 Fingolimod Effect on Cytokine and Chemokine Levels Completed NCT02373098 Phase 4 Fingolimod 0.5 mg
31 Long-term Follow-up of Fingolimod Phase II Study Patients Completed NCT02307838 Phase 4
32 A Double Blind, Randomized, Placebo Controlled, Crossover Study of the Effectiveness of Oral Fampridine in Improving Upper Limb Function in Progressive Multiple Sclerosis Completed NCT02208050 Phase 4 Fampridine;Placebo
33 Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA Completed NCT02205489 Phase 4 Alemtuzumab GZ402673;cetirizine;ranitidine;methylprednisolone;methylprednisolone;aciclovir;esomeprazole;ibuprofen;paracetamol
34 Resistance Training and Amino Pyridine in Multiple Sclerosis Completed NCT02143167 Phase 4 SR-fampridine;Placebo
35 Safety and Efficacy of Natalizumab (BG00002, Tysabri®) in Russian Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Completed NCT02142205 Phase 4
36 Gastrointestinal Tolerability Study Of Dimethyl Fumarate In Participants With Relapsing-Remitting Multiple Sclerosis In Germany Completed NCT02125604 Phase 4 dimethyl fumarate
37 Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Participants With Relapsing-Remitting Multiple Sclerosis Completed NCT02090413 Phase 4 dimethyl fumarate;acetylsalicylic acid;ASA-Placebo
38 A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis Completed NCT02064816 Phase 4 Rebif®;Rebif®
39 Evaluation of the Autonomic Nervous System During First-dosing With 0.5mg of Fingolimod (Gilenya) in Patients With Relapsing-remitting MS Completed NCT02048072 Phase 4 Gilenya
40 Rebif® Rebidose® Versus Rebiject II® Ease-of-Use Completed NCT02019550 Phase 4
41 Study to Compare the Clinical and Radiological Efficacy of 625 mg Versus 1250 mg of Oral Methylprednisolone in Patients With Multiple Sclerosis in Relapse Completed NCT01986998 Phase 4 Methylprednisolone 1250 mg/24h x3 days;Oral Methylprednisolone 625 mg/24h x3 days
42 Safety of Xeomin for Lower Limb Spasticity in Multiple Sclerosis Patients Completed NCT01968902 Phase 4
43 A Randomized Study of Sativex on Cognitive Function and Mood: Multiple Sclerosis Patients Completed NCT01964547 Phase 4 Sativex;Placebo
44 Bladder Management in Patients With Multiple Sclerosis: Optimizing Practice Patterns Completed NCT01930799 Phase 4
45 Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients Completed NCT01895335 Phase 4 Teriflunomide
46 Pilot Clinical Trial of ACTHar Gel 14 Days Subcutaneous (SQ)Versus ACTHar Gel Five Days SQ for the Treatment of MS Exacerbations Completed NCT01888354 Phase 4 H.P. Acthar Gel (repository corticotropin injection)
47 Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United States Completed NCT01873417 Phase 4 BG00012 (DMF)
48 Efficacy of Fish Oil in Multiple Sclerosis Completed NCT01842191 Phase 4
49 Anesthetic Topical Adhesive (Synera™) to Reduce Injection Pain With Subcutaneous Multiple Sclerosis Medications Completed NCT01834586 Phase 4 Anesthetic Topical Adhesive Synera
50 Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis Completed NCT01795872 Phase 4

Search NIH Clinical Center for Autoimmune Disease of the Nervous System

Cochrane evidence based reviews: autoimmune diseases of the nervous system

Genetic Tests for Autoimmune Disease of the Nervous System

Anatomical Context for Autoimmune Disease of the Nervous System

MalaCards organs/tissues related to Autoimmune Disease of the Nervous System:

41
Lung, Skin, Brain, Bone, Eye, Spinal Cord, T Cells

Publications for Autoimmune Disease of the Nervous System

Articles related to Autoimmune Disease of the Nervous System:

# Title Authors Year
1
Human Stem Cell-Derived Models: Lessons for Autoimmune Diseases of the Nervous System. ( 29781367 )
2018
2
Current immune therapies of autoimmune disease of the nervous system with special emphasis to multiple sclerosis. ( 22612753 )
2012
3
Biochemical markers of autoimmune diseases of the nervous system. ( 22612740 )
2012
4
Sphingosine-1-phosphate and its receptors as a possible therapeutic target in autoimmune diseases of the nervous system. ( 19879005 )
2010
5
Inflammatory and autoimmune diseases of the nervous system; possibilities of laboratory diagnostic methods in cerebrospinal fluid. ( 15058200 )
2003
6
Impact of 15-deoxyspergualin on effector cells in experimental autoimmune diseases of the nervous system in the Lewis rat. ( 7527745 )
1994
7
Autoimmune diseases of the nervous system. ( 1096126 )
1975
8
PHENOMENA OF THE CELL MEMBRANE AND THEIR POSSIBLE SIGNIFICANCE FOR THE PATHOGENESIS OF SO-CALLED AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM. ( 14313501 )
1965

Variations for Autoimmune Disease of the Nervous System

Expression for Autoimmune Disease of the Nervous System

Search GEO for disease gene expression data for Autoimmune Disease of the Nervous System.

Pathways for Autoimmune Disease of the Nervous System

Pathways related to Autoimmune Disease of the Nervous System according to GeneCards Suite gene sharing:

(show top 50) (show all 78)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.12 DDX41 HLA-DRB1 IFNB1 IFNG IL10 IL17A
2
Show member pathways
13.76 IFNB1 IFNG IL10 IL17A IL1B IL2
3
Show member pathways
13.64 IFNB1 IFNG IL10 IL17A IL1B IL2
4
Show member pathways
13.51 IL10 IL17A IL1B IL2 IL4 IL6
5
Show member pathways
13.47 HLA-DRB1 IFNB1 IFNG IL10 IL17A IL1B
6
Show member pathways
13.36 IL10 IL17A IL1B IL2 IL4 IL6
7
Show member pathways
13.27 HLA-DRB1 IFNG IL1B IL2 IL4 TLR9
8
Show member pathways
13.13 IFNB1 IFNG IL10 IL1B IL2 IL6
9
Show member pathways
12.99 FOXP3 HLA-DRB1 IFNG IL10 IL17A IL1B
10
Show member pathways
12.92 HLA-DRB1 IFNB1 IFNG IL1B IL2 IL4
11
Show member pathways
12.81 IFNB1 IFNG IL1B IL6 TNF
12
Show member pathways
12.76 IL1B IL2 IL6 TLR9 TNF
13
Show member pathways
12.74 HLA-DRB1 IFNG IL10 IL2 IL4 TNF
14
Show member pathways
12.72 IFNG IL10 IL17A IL1B IL2 IL6
15 12.66 FOXP3 IFNG IL10 IL17A IL1B IL2
16
Show member pathways
12.6 IFNB1 IFNG IL2 IL4 TNF
17
Show member pathways
12.57 IFNG IL10 IL17A IL1B IL2 IL4
18
Show member pathways
12.56 FOXP3 HLA-DRB1 IFNG IL10 IL17A IL1B
19
Show member pathways
12.54 IFNB1 IFNG IL10 IL2 IL4 IL6
20
Show member pathways
12.48 IFNG IL1B IL2 IL4 IL6 TNF
21
Show member pathways
12.48 IFNG IL17A IL1B IL4 IL6 TNF
22 12.46 HLA-DRB1 IL2 IL6 TNF
23
Show member pathways
12.4 HLA-DRB1 IFNG IL10 IL1B IL4 TNF
24
Show member pathways
12.39 IFNB1 IFNG IL10 IL17A IL1B IL2
25
Show member pathways
12.35 IFNG IL1B IL6 TNF
26 12.35 HLA-DRB1 IFNB1 IL6 TNF
27
Show member pathways
12.34 IL10 IL1B IL2 IL6 TLR9 TNF
28
Show member pathways
12.33 IFNB1 IFNG IL1B IL4 IL6 TLR9
29 12.33 HLA-DRB1 IFNB1 IFNG IL10 IL1B IL6
30
Show member pathways
12.32 IFNB1 IL6 TLR9 TNF
31 12.31 AQP4 IL10 IL1B IL6 TNF
32
Show member pathways
12.27 IFNB1 IFNG IL1B TNF
33 12.25 IFNG IL6 TLR9 TNF
34
Show member pathways
12.21 IFNG IL10 IL17A IL1B IL2 IL4
35
Show member pathways
12.18 IFNG IL1B IL4 IL6 TNF
36 12.15 IFNG IL10 IL2 IL4 IL6 TNF
37 12.14 IFNB1 IFNG IL1B TNF
38 12.14 IL10 IL17A IL1B IL4 IL6 S1PR1
39
Show member pathways
12.13 HLA-DRB1 IFNG IL1B IL2 IL4
40
Show member pathways
12.08 IFNG IL10 IL17A IL1B IL2 IL6
41 12.06 IFNB1 IL1B IL6 TNF
42 12.05 HLA-DRB1 IL1B IL4 IL6 TNF
43 12.04 IFNB1 IFNG IL1B IL6
44 12.04 IFNG IL10 IL1B IL6 TNF
45 12.02 IFNB1 IFNG IL10 IL2 IL6
46 12.02 HLA-DRB1 IFNG IL17A IL1B IL6 TNF
47 11.93 IFNG IL2 IL4 IL6
48
Show member pathways
11.91 FOXP3 IFNG IL2 IL4 TNF
49 11.89 IL10 IL1B IL6 TNF
50 11.88 IFNG IL10 IL17A IL1B IL2 IL4

GO Terms for Autoimmune Disease of the Nervous System

Cellular components related to Autoimmune Disease of the Nervous System according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.9 IFNB1 IFNG IL10 IL17A IL1B IL2
2 extracellular space GO:0005615 9.65 IFNB1 IFNG IL10 IL17A IL1B IL2
3 compact myelin GO:0043218 9.26 MAG MBP
4 external side of plasma membrane GO:0009897 9.1 AQP4